Clinical Trial Update: A Phase II Clinical Trial of Suppression of Human Antimouse Antibody and Human Antitoxin Response to Immunotoxin LMB-1 by Rituximab [Phase 2]

View source ↗

Summary

Phase II clinical trial evaluating Rituximab to suppress anti-mouse antibody and anti-toxin responses to the immunotoxin LMB-1 in several cancers; the study sta…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Colorectal Cancer
• Gastric Cancer
• Lung Cancer
• Pancreatic Cancer

Drugs mentioned

• LMB-1
• Rituximab (rituximab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Breast Neoplasms, Colonic Neoplasms | Phase 2 | Status: COMPLETED